Walker & Dunlop, Inc. Files Form 8-K: Company Details, NYSE Listing, and Annual Meeting Results (May 2026) 252627
Walker & Dunlop, Inc. (NYSE: WD) has released the results of its 2026 Annual Meeting of Stockholders, detailing votes on director elections, the ratification of KPMG LLP as independent auditor, and an advisory vote on executive compensation. While most proposals passed with strong support, the executive compensation vote saw significant opposition, signaling shareholder concerns. The company remains listed on the NYSE and is not an emerging growth company, with no immediate price-sensitive corporate actions reported.
Quest Diagnostics (DGX) director granted 1,142 restricted stock units in Form 4 filing
Quest Diagnostics director Robert B. Carter was granted 1,142 restricted stock units (RSUs) on May 20, 2026, as reported in a Form 4 SEC filing. This equity award, valued at $0.00 per share, is a compensation-related grant and not an open-market purchase. Following this transaction, Carter directly holds a total of 3,853 shares of Quest Diagnostics common stock.
Quest Diagnostics (DGX) Announces Results of 2026 Annual Meeting of Stockholders
Quest Diagnostics (DGX) held its 2026 Annual Meeting of Stockholders on May 20, 2026. Key outcomes included the election of directors, approval of executive officer compensation, and ratification of PricewaterhouseCoopers as the independent accounting firm. A proposal for an independent board chairman was not approved, reflecting the company's commitment to governance and transparency.
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting
Quest Diagnostics Inc (NYSE:DGX) held its 2026 Annual Meeting of Stockholders, where shareholders elected all nominated directors and approved the compensation of executive officers and the reappointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm. A stockholder proposal for an independent board chairman was not approved. The company also reported strong first-quarter 2026 financial results, exceeding analyst expectations, and announced a public offering of senior notes and significant dividends.
Director at Quest Diagnostics (DGX) awarded 1,142 restricted stock units
Quest Diagnostics director Timothy M. Ring was awarded 1,142 restricted stock units (RSUs) of common stock, a grant with no cash price per share. Following this transaction, his direct holdings in the company increased to 31,140 shares, which includes shares acquired through dividend reinvestment. This insider transaction was reported as a Form 4 filing and is classified as a neutral event, as it represents compensation rather than an open-market purchase or sale.
Quest Diagnostics (DGX) director receives 1,142 restricted stock units
Quest Diagnostics director Denise M. Morrison was granted 1,142 restricted stock units (RSUs) of Common Stock on May 20, 2026, at no cash cost. This award increased her direct holdings to 11,929 shares, which also includes shares acquired through dividend reinvestment since her previous Form 4 filing. The transaction is a compensation-related equity grant, not an open-market purchase.
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 stock units
Quest Diagnostics director Wright Lassiter III was granted 1,142 restricted stock units on May 20, 2026, which is a compensation-related award rather than an open-market purchase. Following this transaction, Lassiter III directly holds 10,317 shares, a figure that includes shares acquired through dividend reinvestment under the company's Deferred Compensation Plan for Directors. This grant aligns the director's interests with company performance.
Director Tracey Doi of Quest Diagnostics (DGX) receives 1,142-share equity award
Quest Diagnostics director Tracey Doi received an equity award of 1,142 shares of Common Stock as a grant, which were restricted stock units with no cash price per share. Following this award and dividend reinvestments, her direct holdings in Quest Diagnostics (DGX) now total 7,748 shares. This transaction is classified as compensation-related rather than an open-market purchase, as detailed in the SEC Form 4 filing.
Quest Diagnostics (DGX) director gets 1,142-share restricted stock unit award
Quest Diagnostics director Timothy C. Wentworth received an award of 1,142 restricted stock units (RSUs) of Common Stock, increasing his total holdings to 1,358 shares. The grant was valued at $0.00 per share, indicating a compensation-related equity award rather than a stock purchase. His holdings also include shares acquired through dividend reinvestment under the company's deferred compensation plan for directors.
Quest Diagnostics (DGX) director receives 1,142-share restricted stock unit grant
Quest Diagnostics director Timothy L. Main was granted 1,142 restricted stock units (RSUs) on May 20, 2026, as part of his compensation. This award, valued at $0.00 per share, increased his direct holdings of Common Stock to 27,439 shares. The transaction is classified as a grant or award acquisition and reflects equity-based compensation rather than an open-market purchase or sale.
Health-ISAC: How Claude Mythos could impact healthcare cybersecurity
Anthropic's Claude Mythos, an AI model with autonomous offensive cybersecurity capabilities, could significantly impact vulnerable sectors like healthcare if misused, according to a recent threat bulletin from Health-ISAC. While Anthropic created Claude Mythos Preview for identifying vulnerabilities, its potential for abuse and the rapid proliferation of similar tools by late 2026 pose a systemic risk to critical infrastructure. Health-ISAC warns that the success and risk levels of this technology depend on effective management of its rollout and preventing unauthorized access, referencing the Cobalt Strike tool as a cautionary tale.
Lumexa Imaging Under Investigation for Data Breach
Schubert Jonckheer & Kolbe LLP is investigating a data breach at Lumexa Imaging, a diagnostic imaging provider. The breach, which occurred between March 31 and April 9, 2026, exposed sensitive patient data, including names, dates of birth, Social Security numbers, and medical information, through a vendor’s compromised system. Lumexa has not yet reported the incident to state attorney general offices, and individuals impacted may be entitled to damages as the law firm explores legal recourse.
Why Guardant Health (GH) Is Up 16.8% After Hiking 2026 Revenue Guidance on Shield Momentum
Guardant Health's stock rose 16.8% after the company raised its 2026 revenue guidance to US$1.30–US$1.32 billion, driven by strong adoption of its Shield colorectal cancer screening test. While the increased guidance highlights confidence in Shield's momentum and broader market access through Quest Diagnostics, the company continues to face widening losses and cash burn. The investment narrative remains centered on Shield's potential to scale into a commercially reimbursed market, balanced against ongoing funding and dilution risks.
Reasons to Add Align Technology Stock to Your Portfolio Now
Align Technology (ALGN) is positioned for growth due to its expanding Invisalign business and iTero intraoral scanning technology. While the company exhibits strong financial stability with no debt and significant cash reserves, it faces challenges from decreasing average selling prices (ASPs). The article suggests ALGN is a strong buy, highlighting its positive earnings surprise history and growth projections despite recent stock performance.
Guardant Health Stock Rallies After Shield-Fueled Earnings Beat
Guardant Health (GH) stock rallied 13.38% after strong Q1 earnings, fueled by a 48% year-over-year revenue increase to $302 million and a significant surge in Shield screening revenue. The company raised its FY26 revenue outlook to $1.30B–$1.32B and secured a nationwide collaboration with Quest Diagnostics, which analysts expect to drive further growth. Despite continued negative free cash flow, bullish ratings from major banks and increased price targets reflect confidence in Guardant Health's growth trajectory and market leadership in liquid biopsy.
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist
This article identifies three promising "penny stocks" – Cardiff Oncology (CRDF), OraSure Technologies (OSUR), and Endava (DAVA) – combining financial resilience with growth potential despite their current challenges. While the US market shows fluctuations, these companies are highlighted for their strategic developments, market positions, and future prospects based on financial health analyses. The piece emphasizes that the information is general and not financial advice, encouraging readers to conduct their own due diligence.
Quest Diagnostics Inc. stock outperforms competitors on strong trading day
Shares of Quest Diagnostics Inc. (DGX) increased by 1.76% to $193.75 on Wednesday, outperforming competitors on a strong trading day for the stock market. Both the S&P 500 Index and the Dow Jones Industrial Average also saw significant rises. This marks the third consecutive day of gains for Quest Diagnostics stock.
Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics (NYSE: DGX) announced that its Board of Directors has declared a quarterly cash dividend of $0.86 per share. The dividend is payable on July 22, 2026, to shareholders of record as of July 8, 2026. Quest Diagnostics is a leading provider of diagnostic information services, connecting clinicians and consumers with laboratory insights to improve health outcomes.
Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time
Labcorp has launched MyLabcorp™, an AI-powered mobile app designed to help consumers understand their lab results and track health trends over time. The app integrates lab results, AI-enabled insights, and educational content, leveraging OpenAI models for personalized explanations and conversational interactions. It aims to empower users with better health context and support more informed discussions with healthcare providers, all within a secure, HIPAA-compliant environment.
New Labcorp app uses OpenAI to explain your lab results
Labcorp has launched MyLabcorp, an AI-powered mobile app designed to help consumers understand their lab results and track health trends over time. The HIPAA-compliant app integrates Labcorp test results with OpenAI-powered explanations and clinically reviewed educational content. This initiative aims to address the growing consumer demand for clearer health information by providing personalized insights and facilitating more informed conversations with healthcare providers.
Labcorp joins lab results personalization push with ‘MyLabcorp’ AI app
Labcorp has launched "MyLabcorp," a new mobile app that uses AI and clinical guidelines to help patients understand their lab test results and support better conversations with healthcare providers. The app aims to address the growing trend of consumers using AI for health information by providing curated, context-rich explanations and educational content. This move positions Labcorp among other diagnostic companies and healthcare platforms that are incorporating AI to personalize health insights for users.
Quest Diagnostics Declares Quarterly Cash Dividend
Quest Diagnostics (NYSE: DGX) announced that its Board of Directors has declared a quarterly cash dividend of $0.86 per share. This dividend is payable on July 22, 2026, to shareholders of record as of July 8, 2026. Quest Diagnostics is a leader in diagnostic information services, aiming to improve healthcare through laboratory insights and testing.
Quest Diagnostics Keeps Quarterly Dividend at $0.86 a Share, Payable July 22 to Holders of Record July 8
Quest Diagnostics (DGX) has announced it will maintain its quarterly dividend at $0.86 per share. The dividend is scheduled to be paid on July 22 to shareholders of record as of July 8. This decision signals consistent returns for investors in the healthcare diagnostics provider.
$0.86 a share: Quest Diagnostics dividend hits investors in July
Quest Diagnostics (NYSE: DGX) has declared a quarterly cash dividend of $0.86 per share. This dividend is scheduled to be paid on July 22, 2026, to shareholders who are on record as of July 8, 2026. The announcement was made by the company's Board of Directors.
Is This the Right Time to Hold DGX Stock in Your Portfolio?
Quest Diagnostics (DGX) is showing strong growth potential, particularly in its Diagnostic Information Services (DIS) segment and Advanced Diagnostics. The company's strategic initiatives, including enterprise-wide AI adoption and its Invigorate program, are expected to drive operational improvements and continued financial performance. While facing challenges such as escalating debt levels and macroeconomic volatility, the stock continues to receive a "Buy" rating from Zacks.
Is This the Right Time to Hold DGX Stock in Your Portfolio?
Quest Diagnostics (DGX) is showing strong growth potential, particularly in its Diagnostic Information Services and Advanced Diagnostics segments, with an earnings yield of 5.73%. Despite concerns about escalating debt and macroeconomic volatility, the company's operational excellence initiatives and strategic partnerships are poised to drive future performance. Analysts also predict significant earnings per share and revenue growth for 2026, making it a "Buy" rated stock according to Zacks.
Quest Diagnostics Inc. stock outperforms competitors on strong trading day
Shares of Quest Diagnostics Inc. (DGX) rose 1.73% to $189.84 on Monday, outperforming the S&P 500 Index which slightly fell, and the Dow Jones Industrial Average which saw a modest rise. This gain ended a two-day losing streak for the stock.
Baird Adjusts Price Target on Quest Diagnostics to $232 From $229, Maintains Neutral Rating
Baird has adjusted its price target for Quest Diagnostics (DGX) to $232, an increase from the previous target of $229. The firm has decided to maintain a Neutral rating on the company's stock. This update reflects Baird's ongoing assessment of Quest Diagnostics' financial outlook and market position.
Canada Post Corp Registered Pension Plan Sells 5,785 Shares of Quest Diagnostics Incorporated $DGX
Canada Post Corp Registered Pension Plan reduced its stake in Quest Diagnostics (NYSE:DGX) by 20.1% in the fourth quarter, selling 5,785 shares and retaining 23,015 shares valued at $3.99 million. Quest Diagnostics reported strong Q1 results, exceeding EPS and revenue expectations, and reaffirmed its FY 2026 EPS guidance. Analysts generally maintain a "Moderate Buy" rating with an average target price of $216.58, and the company has a $1 billion share buyback authorization.
Have Guardant Health Insiders Been Selling Stock?
Guardant Health (NASDAQ:GH) has seen significant insider selling recently, with Co-CEO AmirAli Talasaz selling shares worth $5.0m and co-founder Helmy Eltoukhy selling $18m worth below the current price. While insiders own a healthy 3.8% of the company, the consistent selling without corresponding purchases raises caution for potential investors. The article highlights that such selling is a weak signal but suggests that insiders might view current valuations as high.
International Assets Investment Management LLC Purchases New Shares in Quest Diagnostics Incorporated $DGX
International Assets Investment Management LLC recently acquired 55,228 shares of Quest Diagnostics, valued at approximately $92,000, during the fourth quarter. Quest Diagnostics reported strong quarterly earnings, beating analyst expectations with $2.50 EPS and $2.90 billion in revenue, alongside a 9.2% year-over-year revenue increase. The company's board also authorized a $1.0 billion share repurchase program, indicating confidence in its valuation.
Quest Diagnostics Incorporated $DGX Shares Acquired by ANTIPODES PARTNERS Ltd
ANTIPODES PARTNERS Ltd significantly increased its stake in Quest Diagnostics, now holding over 171,000 shares valued at $29.8 million. The company reported strong Q4 results, exceeding revenue and EPS estimates, and announced a $1 billion share repurchase plan. Wall Street analysts maintain a "Moderate Buy" rating with a consensus target price of $216.58.
173,262 Shares in Quest Diagnostics Incorporated $DGX Bought by Conning Inc.
Conning Inc. recently acquired a new stake of 173,262 shares in Quest Diagnostics (DGX) worth approximately $30.1 million, increasing institutional ownership to 88.06%. This comes as Quest Diagnostics reported stronger-than-expected quarterly earnings with an EPS of $2.50 and revenue of $2.90 billion, leading to a "Moderate Buy" consensus rating among analysts. Despite some insider selling, analysts have maintained or raised their price targets, and the company has authorized a $1 billion share repurchase program.
Veracyte Gains Medicare Coverage for Muscle-Invasive Bladder Cancer Recurrence Monitoring Test
Veracyte's TrueMRD Monitoring Test has received Medicare coverage for recurrence monitoring in patients with muscle-invasive bladder cancer (MIBC) following definitive treatment. This makes it Veracyte’s first molecular residual disease (MRD) commercial offering and the first commercially available whole-genome MRD test on the market. The test, which launches June 1, 2026, aims to improve early detection of recurrence and inform treatment decisions, especially as MIBC patients have a high recurrence rate within two years.
Quest Diagnostics stock (US74834L1008): $500M notes offering announced
Quest Diagnostics (US74834L1008) launched a $500 million senior notes offering on May 13, 2026, aimed at strengthening its balance sheet and supporting growth in diagnostic services across the US. The company, a major player in diagnostic information services with a market cap of $21.13 billion, operates an extensive network of labs and patient service centers. This move underscores its strategy to fund growth in the vital US-focused healthcare market, providing investors exposure to the essential diagnostics segment.
Labcorp stock (US50540R4092): Q1 earnings beat with $4.25 EPS
Labcorp reported stronger-than-expected Q1 2026 earnings, with adjusted EPS of $4.25 and revenue growth of 5.8% to $3.54 billion, surpassing analyst forecasts. The company's performance was driven by its core clinical laboratory testing and drug development services. Labcorp's significant exposure to the US healthcare system and its position in the diagnostics industry contribute to its resilience for investors.
Insight Molecular Q1 2026 Earnings Call Transcript
Insight Molecular (NASDAQ: IMDX) held its Q1 2026 earnings call, detailing the submission of GraftAssuredX to the FDA in March 2026 and positive market research outcomes. The company projects Q2 2026 revenue of $250,000 and a high cash burn of over $9 million, expected to decrease in the latter half of the year. Key initiatives include expanding the Galactic Registry study, targeting regulatory compliance in Europe and the UK, and moving into heart transplant testing with the goal of long-term gross margins around 70%.
Evaluating Labcorp Holdings (LH) After Expanded Epic Partnership And An 18% Estimated Valuation Gap
Labcorp Holdings (LH) recently expanded its partnership with Epic, integrating its diagnostic test menu into Epic's Aura platform to streamline ordering and results for healthcare systems. Despite recent short-term share price softening, the company is estimated to be 18% undervalued with a fair value of $310.06 per share. This valuation is supported by anticipated growth from innovative tests, enhanced operational efficiencies through AI and technology, and tighter cost discipline, although potential risks from regulatory changes or increased competition could challenge this upside.
Becton Dickinson (BIT:1BDX) - Stock Analysis
Becton Dickinson (BIT:1BDX) is trading below its estimated fair value with earnings forecast to grow by 9.63% per year, and pays a reliable dividend of 2.91%. The company recently appointed a new CFO, declared a quarterly dividend, and launched several innovative medical products including the BD CentroVena One Insertion System and the BD PureWick Urine Collection System. Becton Dickinson continues to expand its portfolio with advancements in portal hypertension care, AI-powered immunology research tools, breast biopsy systems, and connected care platforms.
Quest Diagnostics USD500M Notes Offering
A&O Shearman advised Quest Diagnostics Incorporated on its registered offering of USD500 million aggregate principal amount of its 5.000% senior notes due 2036. The legal team involved partners Erika Kent and Lona Nallengara, along with various associates and counsel specializing in Capital Markets, Funds, and Tax. Quest Diagnostics is a major provider of diagnostic insights from laboratory testing.
MDxHealth (NASDAQ: MDXH) posts Q1 2026 growth and issues new 2026 guidance
MDxHealth reported Q1 2026 revenue of $27.4 million, a 13% increase year-over-year, alongside an operating loss of $7.3 million and a net loss of $8.9 million. The company announced it would discontinue its Resolve UTI business and close its Plano, Texas lab to focus on prostate cancer diagnostics and the ExoDx acquisition. MDxHealth also issued new 2026 core cancer revenue guidance of $110–115 million, representing 20–26% growth, and is contesting a $10.4 million Medicare recoupment decision related to historical Resolve claims.
Quest Diagnostics stock (US74834L1008): Diagnostic leader strengthens balance sheet with $500M notes
Quest Diagnostics has announced a $500 million senior notes offering to strengthen its financial position and support ongoing operations and potential investments in diagnostic capabilities. The company, a major U.S. clinical laboratory network, generates revenue primarily through laboratory testing services for healthcare providers, employers, and consumers. This move provides financial flexibility for Quest Diagnostics, a cornerstone player in the U.S. healthcare infrastructure, offering investors exposure to an essential healthcare services business.
Quest Diagnostics Incorporated $DGX Shares Acquired by Ethic Inc.
Ethic Inc. increased its stake in Quest Diagnostics (NYSE:DGX) by 41.4% in the fourth quarter, bringing its total holdings to 20,391 shares valued at $3.54 million. This comes after Quest Diagnostics reported strong quarterly earnings, beating revenue and EPS estimates, and authorized a $1 billion share buyback program. Analysts currently maintain a "Moderate Buy" rating with an average price target of $216.58 for the stock.
Exagen Inc stock (US30063K1051): Q1 revenue hits record $17.3M, up 12%
Exagen Inc. reported a record Q1 revenue of $17.3 million, a 12% increase year-over-year, and reaffirmed its full-year 2026 revenue guidance between $70-73 million. The company specializes in molecular diagnostics for autoimmune diseases, with its Avise tests driving significant growth. Despite BTIG lowering its price target due to valuation, Exagen continues to target the expanding autoimmune diagnostics market.
How Illumina employees work to move healthcare toward precision medicine
Illumina's Medical Affairs team is dedicated to advancing precision medicine by promoting genomic literacy, generating evidence, and overcoming barriers to genomic testing. This global team of over 30 experts, many with extensive clinical lab experience, educates healthcare providers, collaborates on research, and supports product development. Their work aims to integrate genomics into mainstream medicine, improve patient benefits, and address challenges such as complex data interpretation and reimbursement hurdles.
Quest Diagnostics Inc. stock outperforms competitors on strong trading day
Quest Diagnostics Inc. (DGX) stock rose 1.29% to $189.81 on Monday, outperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw a 0.19% increase. Despite this gain, Quest Diagnostics Inc. remains 11.10% below its 52-week high.
Is NeoGenomics’ Higher 2026 Revenue Outlook And Narrower Loss Profile Altering The Investment Case For NEO?
NeoGenomics recently revised its 2026 revenue guidance upwards and reported a narrower net loss for Q1 2026, driven by growing oncology test adoption. While these improvements suggest increasing traction for its cancer testing platform, the company remains loss-making, and investors should consider the ongoing risk posed by its high fixed costs and infrastructure investments against its revenue growth. The narrative projects significant revenue and earnings growth by 2029, suggesting a potential undervaluation.
Digi Power X Expands ATM Program to Fund Growth
Digi Power X announced an expansion of its at-the-market equity offering program by US$100 million, bringing the total to US$175 million to fund growth initiatives. Proceeds will support general corporate purposes, data center construction, debt repayment, and acquisitions for its AI and high-performance computing network. While seen as a move to strengthen its competitive position in AI infrastructure, TipRanks' AI Analyst "Spark" rates DGX as Neutral due to weak financial performance and uncertain valuation.
How Investors May Respond To Option Care Health (OPCH) Revenue Guidance Cut And Chronic Therapy Headwinds
Option Care Health (OPCH) recently reported Q1 2026 results and cut its full-year revenue guidance due to headwinds in its chronic therapy segment. This revision has triggered securities law investigations and raised concerns about management's ability to foresee patient census trends and therapy mix shifts. The article explores how these challenges and the guidance cut may impact OPCH's long-term investment outlook, emphasizing the need for management to stabilize chronic inflammatory disease volumes and manage payer relationships.
Guardant Health, Inc. (NASDAQ:GH) Q1 2026 Earnings Call Transcript
Guardant Health, Inc. reported strong financial results for Q1 2026, with total revenue increasing 48% year-over-year to $302 million, exceeding expectations despite an EPS miss. The growth was broad-based across its Oncology, Biopharma & Data, and Screening business lines, with significant momentum from its Shield colorectal cancer screening test and the Guardant360 Liquid and Tissue platforms. The company raised its full-year 2026 revenue guidance to $1.30 billion to $1.32 billion, driven by continued adoption of its oncology products and the successful commercial launch of Shield, including collaborations and marketing campaigns.
